Patents Issued in September 14, 2010
  • Patent number: 7794944
    Abstract: The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: September 14, 2010
    Assignee: University of Utah Research Foundation
    Inventor: Brice Felden
  • Patent number: 7794945
    Abstract: Conjugates between a minor groove binding molecule, such as the trimer of 1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI3), and an oligonucleotide form unusually stable hybrids with complementary target sequences, in which the tethered CDPI3 group resides in the minor groove of the duplex. These conjugates can be used as probes and primers. Due to their unusually high binding affinity, conjugates as short as 8-mers can be used as amplification primers with high specificity and efficiency. MGB conjugation also increases the discriminatory power of short oligonucleotides, providing enhanced detection of nucleotide sequence mismatches by short oligonucleotides.
    Type: Grant
    Filed: July 14, 2008
    Date of Patent: September 14, 2010
    Assignee: Elitech Holding B.V.
    Inventors: Joel Hedgpeth, Irina A. Afonina, Igor V. Kutyavin, Eugeny A. Lukhtanov, Evgeniy S. Belousov, Rich B. Meyer, Jr.
  • Patent number: 7794946
    Abstract: The invention disclosed herein comprises methods of using microarrays to simplify analysis and characterization of genes and their function. In one aspect of the invention the methods are used to identify and characterize antibodies having binding affinity for a specific target antigen. The invention further comprises a method of determining gene expression at the protein level comprising contacting an array of characterized or uncharacterized antibodies on a solid surface with one or more proteins and identifying the antibodies to which said protein(s) binds. This method can be additionally used to compare the protein expression in two different populations of cells, such as normal cells and cancer cells or resting cells and stimulated cells.
    Type: Grant
    Filed: February 4, 1999
    Date of Patent: September 14, 2010
    Assignee: Life Technologies Corporation
    Inventors: James P. Hoeffler, Joseph M. Fernandez, Marc S. Nasoff
  • Patent number: 7794947
    Abstract: The invention provides methods of detecting polypeptides in a sample. The method can include the steps of cleaving polypeptides in a test sample to generate peptides; adding a predetermined amount of isotopically labeled peptide standards to the cleaved test sample, wherein the peptide standards correspond to peptides cleaved with the same reagent used to cleave the test sample; contacting the cleaved test sample containing peptide standards with an array of immobilized binding agents specific for the peptide standards; washing the array to remove unbound peptides, thereby retaining affinity captured sample peptides and standard peptides; analyzing the affinity captured peptides using mass spectrometry; and determining the presence of bound test peptides and standard peptides. The method can further include the step of quantifying the amount of the test peptides by comparing the ratio of test peptide to corresponding standard peptide.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: September 14, 2010
    Assignee: Institute for Systems Biology
    Inventors: Rudolf H. Aebersold, Hui Zhang
  • Patent number: 7794948
    Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's or non-Alzheimer's dementia or normal. The biomarkers can be detected by SELDI mass spectrometry. In addition, the invention provides appropriate treatment interventions and methods for measuring response to treatment. Certain biomarkers of the invention may also be suitable for employment as radio-labeled ligands in non-invasive imaging techniques such as Positron Emission Tomography (PET).
    Type: Grant
    Filed: November 6, 2004
    Date of Patent: September 14, 2010
    Assignee: Vermilllion, Inc.
    Inventors: Huw Alun Davies, James McGuire, Anja Hviid Simonsen, Kaj Blennow, Vladimir Podust
  • Patent number: 7794949
    Abstract: The present invention provides biomarkers of chronic pelvic pain syndrome for use in diagnosis, drug screening, therapy monitoring, research and therapeutic applications. In particular, the present invention provides MCP-1 and MIP-1? as biomarkers of chronic pelvic pain syndrome.
    Type: Grant
    Filed: April 27, 2005
    Date of Patent: September 14, 2010
    Assignee: Northwestern University
    Inventors: Anthony J. Schaeffer, Alisa E. Koch
  • Patent number: 7794950
    Abstract: An object of the present invention is to provide a novel method for detecting irradiation treatment of foods. The present invention provides a method for detecting irradiation treatment of foods comprising the steps of (A) obtaining a fraction containing one or more irradiation-generated fragments of natural high-molecular weight compound(s) from a food sample, and (B) reacting the fraction with one or more antibodies capable of recognizing the one or more fragments, thereby detecting the one or more fragments. The invention also provides a kit for detecting irradiation treatment of foods.
    Type: Grant
    Filed: June 6, 2005
    Date of Patent: September 14, 2010
    Assignee: Nissin Food Products Co., Ltd.
    Inventors: Yukio Yoneda, Toshihiro Yamada
  • Patent number: 7794951
    Abstract: The present invention relates to methods and compositions for modulating fertility. In particular the present invention provides cell lines and transgenic animals for use in identifying modulators of SREBP2gc transcription factors. The present invention further provides therapeutic agents that modulate SREBP2gc signaling for use as fertility modulators.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: September 14, 2010
    Assignee: University of Massachusetts Medical School
    Inventors: Daniel Kilpatrick, Hang Wang
  • Patent number: 7794952
    Abstract: The present invention relates to compositions and methods for characterizing the physiological state of a living system, including cells, tissues, organs, and whole organisms. The methods involve capturing biomarkers from the living system, and correlating their presence or absence to a physiological state. The biomarkers can be captured from the system, and then detected using any suitable analytical system to determine their presence or absence. In one embodiment, the invention relates to a method of detecting a polypeptide biomarker in a blood serum or plasma sample obtained from a single subject with an affinity ligand which is capable of binding to a plurality of different polypeptide biomarkers derived from the same parental molecule.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: September 14, 2010
    Assignee: George Mason University
    Inventors: Lance Liotta, Emanuel Petricoin
  • Patent number: 7794953
    Abstract: The present invention relates to detection of the presence or absence of cerebrospinal fluid (CSF) in a sample, in particular to the analysis of the CSF protein lipocalin-type prostaglandin D2 synthase (L-PGDS). The present invention provides assays for the analysis of PGDS indicating the presence or absence of CSF in a sample.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: September 14, 2010
    Assignee: Stony Brook Anaesthesiology, Univeristy Faculty Practice Corporation
    Inventor: Srinivas N. Pentyala
  • Patent number: 7794954
    Abstract: A non-radioisotopic method of detecting thyroid analytes comprising detecting T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in a sample of a non-human species. Each one of these analytes in an assay profile includes non-radio isotopic measurement of T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in the sample from the non-human species. A non-radioisotopic method detects T3AA and T4AA thyroid autoantibodies in a sample from a non-human species such as the canine species. A non-radioisotopic method detects Free T4 in a sample of a non-human species.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: September 14, 2010
    Assignee: Hemopet
    Inventors: W. Jean Dodds, Ferdie S. Ongchangco
  • Patent number: 7794955
    Abstract: A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise. The method uses a transmembrane protein that comprises a nuclear localisation sequence (NLS).
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: September 14, 2010
    Assignee: Patobios Ltd.
    Inventors: Brian F. O'Dowd, Susan R. George
  • Patent number: 7794956
    Abstract: The invention is directed to the regulation of glucose homeostasis by modulating the activity of Grb2-associated binder 1 (Gab1) in hepatocytes. This invention also provides for a method for identifying compounds capable of modulating the glucose homeostasis regulatory activity of Gab1. In one aspect, the invention provides a method for identifying a compound that can effectively modulate glucose homeostasis wherein Gabl mediated MapK activity indicates that the candidate compound is an effective compound that modulates glucose homeostasis. In another aspect, the invention provides a method for identifying a compound that can effectively modulate the glucose homeostasis regulating activity of Gabl wherein MAPK is activated to phosphorylate Serine residue 612 of IRS-1, indicating that the candidate compound is an effective compound that modulates glucose homeostasis. In another aspect of the invention is provided a method for diagnosing Gab1 related disorders.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: September 14, 2010
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Gen-Sheng Feng, Emilie Chapeau
  • Patent number: 7794957
    Abstract: The present invention relates to regulation of adult lifespan in eukaryotes. More particularly, the present invention is directed to methods of assaying for activators of the heat shock factor 1 (HSF-1) protein, which increases lifespan when overexpressed in an organism.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: September 14, 2010
    Assignee: Regents of the University of California
    Inventors: Cynthia Kenyon, Javier Apfeld, Andrew Dillin, Delia Garigan, Ao-Lin A. Hsu, Josh Lehrer-Graiwer, Coleen Murphy
  • Patent number: 7794958
    Abstract: Provided herein is a method for diagnosing and monitoring endometriosis in a subject by measuring levels of the ?-subunit of fibrinogen.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: September 14, 2010
    Assignee: The Board of Trustees of the University of Illinois
    Inventor: Asgerally T. Fazleabas
  • Patent number: 7794959
    Abstract: The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in hydrolyzed soy protein derived materials. The invention further relates to the use of these T2R receptors in assays for identifying ligands that modulate the activation of these taste receptors by specific bitter ligands present in hydrolyzed soy protein materials and derivatives thereof and related compounds. These compounds may be used as additives and/or removed from soy-based foods, beverages, cosmetics and medicinals in order to modify (block) T2R-associated bitter taste elicited by bitter ligands present in hydrolyzed soy protein materials.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: September 14, 2010
    Assignee: Senomyx, Inc.
    Inventors: Xiaodong Li, Hong Xu, Lan Zhang, Hanghui Liu, Keping Wu
  • Patent number: 7794960
    Abstract: The use of various biomarkers to assess a subject's suitability for treatment with a EGFR/ErbB2 kinase inhibitor for a solid tumor are described. The biomarkers include TGFalpha, pS6, IGF-1R and levels of apoptosis occurring in tumor tissue.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: September 14, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Neil Lee Spector, Albert Man
  • Patent number: 7794961
    Abstract: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP.
    Type: Grant
    Filed: January 9, 2007
    Date of Patent: September 14, 2010
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: John C. Reed, Quinn Deveraux, Guy S. Salvesen, Ryosuke Takahashi, Natalie Roy
  • Patent number: 7794962
    Abstract: The invention provides a method for the expression of exogenous DNA libraries in filamentous fungi. The fungi are capable of processing intron-containing eukaryotic genes, and also can carry out post-translational processing steps such as glyclosylation and protein folding. The invention provides for the use of fungi with altered morphology, which permits high-throughput screening and directed molecular evolution of expressed proteins. The same transformed fungi may be used to produce larger quantities of protein for isolation, characterization, and application testing, and may be suitable for commercial production of the protein as well.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: September 14, 2010
    Assignee: Dyadic International (USA), Inc.
    Inventors: Mark A. Emalfarb, Peter J. Punt, Cornelia van Zeijl, Cornelius van den Hondel
  • Patent number: 7794963
    Abstract: A process of in vivo labeling and identifying recombinantly produced peptides or proteins within an unpermeabilized prokaryotic host cell. Recombinant prokaryotic cells expressing a fusion peptide comprising at least one tetracysteine tag were labeled in vivo using a biarsenical labeling reagent. A fluorescent activated cell sorter was used to identify and select subpopulations of fluorescent cells wherein the amount of fusion peptide in the cell was proportional to the amount of fluorescence detected.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: September 14, 2010
    Assignee: E.I. du Pont de Nemours and Company
    Inventors: Qiong Cheng, Kevin Michael Croker, Stephen R. Fahnestock, Tanja Maria Gruber, Kristin Ruebling-Jass, Jianzhong Zhang
  • Patent number: 7794964
    Abstract: The present invention relates to a biochip for detecting phosphorylation and a method for detecting phosphorylation using the same, more precisely a biochip prepared by integrating a protein produced from the recombination of a substrate of kinase selected from the group consisting of PKC (Protein Kinase C), cdc2-PK (cdc2 Protein Kinase) and DNA-PK (DNA-dependent Protein Kinase) and the elevated protein such as Selenomonas ruminantium membrane protein on a matrix surface coated with an active group, a kit for detecting phosphorylation composed of the said biochip and a cofactor labeled with a radio-isotope and a method for detecting phosphorylation using the same. The biochip for detecting phosphorylation of the present invention using a radio-isotope facilitates the detection of phosphorylation with a minimum amount of a sample by simple processes, compared with the conventional method using an antibody.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: September 14, 2010
    Assignee: Korea Atomic Energy Research Institute
    Inventors: Sang-Hyun Park, Kyong Cheol Ko
  • Patent number: 7794965
    Abstract: The invention relates to methylated proteins that control protein phosphorylation, particularly phosphoesterases, such as PP2A. It relates to screening methods for determining agents that affect methylation of these proteins and thus also modulate the level of phosphorylation of phosphoproteins. It relates as well to the agents and to compositions comprising the agents. In a particular aspect in this regard the invention relates to agents that alter PP2A methylation and that thereby affect phosphorylation of phosphoproteins that play an important role in health or disease, such as the tau protein which is implicated in the etiology of Alzheimer's Disease. The invention further relates to diagnostic methods based on protein methylation levels, to compositions comprising agents for affecting methylation of proteins and for controlling the phosphate complement of phosphoproteins.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: September 14, 2010
    Assignees: Signum Biosciences, Inc., The Trustees of Princeton University
    Inventors: Gregory Stock, Jeffry B. Stock, Maxwell Stock, Scott Vafai
  • Patent number: 7794966
    Abstract: The present invention aims to enable highly reliable measurement of a glycated amine. A fructosyl amino acid oxidase (FAOD) is added to a sample to remove a non-analyte glycated amine that is present in the sample and different from an analyte glycated amine. Thereafter, a protease is added to the sample to degrade the analyte glycated amine, and the degradation product of the analyte glycated amine reacts with the FAOD that has already been added to the sample. By measuring this redox reaction, the amount of the analyte glycated amine can be measured.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: September 14, 2010
    Assignee: Arkray, Inc.
    Inventor: Kaoru Hirai
  • Patent number: 7794967
    Abstract: The present invention relates to a method for detection of novel pathogen inhibitors using models of pathogen specific, and metal binding structures/domains representing essential cellular molecules. The method enables identification of inhibitors that bind to any specific RNA molecule or protein that are essential for cell growth, proliferation and differentiation. The invention also relates to a kit for use in the method. Furthermore, the invention relates to use of aminoglycosides in the development of new drugs.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: September 14, 2010
    Assignee: Bioimics AB
    Inventors: Anders Virtanen, Leif Kirsebom
  • Patent number: 7794968
    Abstract: The invention provides a colorimetric and/or fluorescent detector, which is a solid organic matrix, most preferably in the form of a gel, comprising polydiacetylene(s) and one or more lipids. Processes for preparing the detector and methods for using the same, including for the detection of microorganism suspected to be present in food products, are also provided.
    Type: Grant
    Filed: January 9, 2006
    Date of Patent: September 14, 2010
    Assignee: Ben-Gurion University of the Negev Research and Development Authority
    Inventor: Raz Jelinek
  • Patent number: 7794969
    Abstract: The present disclosure identifies methods and compositions for modifying photoautotrophic organisms as hosts, such that the organisms efficiently convert carbon dioxide and light into n-alkanes, and in particular the use of such organisms for the commercial production of n-alkanes and related molecules.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: September 14, 2010
    Assignee: Joule Unlimited, Inc.
    Inventors: Nikos Basil Reppas, Christian Perry Ridley
  • Patent number: 7794970
    Abstract: Methods for generating F(ab?)2 fragments from antibodies using thermolysin as well as F(ab?)2 fragments and compositions comprising F(ab?)2 fragments generated by the method are described.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: September 14, 2010
    Assignee: Amgen Inc.
    Inventors: John O. Hui, Mitsuru Haniu, Hsieng Sen Lu
  • Patent number: 7794971
    Abstract: The present invention provides compositions and methods for controlling the copy number for a broad range of plasmids and uses thereof. Disclosed is a host cell for conditional control of copy number of a plasmid, which host cell comprises a poly(A) polymerase gene that is operably joined to a conditionally inducible promoter, and a method for cloning and stably maintaining a DNA sequence encoding a heterologous polypeptide in the host cell.
    Type: Grant
    Filed: July 1, 2004
    Date of Patent: September 14, 2010
    Assignee: Epicentre Technologies Corporation
    Inventors: Darin J. Haskins, Leslie M. Hoffman
  • Patent number: 7794972
    Abstract: Novel benzoate- or anthranilate-inducible promoters, and novel tandem promoters, and variants and improved mutants thereof, useful for commercial prokaryotic fermentation systems, nucleic acid constructs containing the promoters, expression systems using them, methods for expressing proteins by use thereof, and proteins expressed thereby.
    Type: Grant
    Filed: January 3, 2005
    Date of Patent: September 14, 2010
    Assignee: Pfenex Inc.
    Inventors: Diane M. Retallack, Venkiteswaran Subramanian
  • Patent number: 7794973
    Abstract: A novel gene, dubbed “YS68”, involved in primitive hematopoiesis was successfully isolated from cDNA derived from mouse yolk sacs. In addition, a human gene corresponding to this gene was successfully isolated. Expression characteristics of these genes suggested their involvement in primitive hematopoiesis. The proteins of this invention and genes encoding the proteins may be utilized as tools for drug development against diseases, such as hematological disorders.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: September 14, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tetsuya Taga, Naoki Kimura
  • Patent number: 7794974
    Abstract: The present invention relates to functional cDNA and genomic sequences encoding PrtT proteins, which have transcriptional activity on a protease promoter, to PrtT proteins and to their use. The invention further relates to two distinct types of filamentous fungal cells. Filamentous fungal cells are transformed to over-express these PrtT proteins: this type of filamentous fungus will be highly suited as protease producer. Alternatively, the endogenous prtT genes of filamentous fungal cells are inactivated: this type of filamentous fungus is highly suited for the production of any polypeptide native or not which is highly sensitive for protease degradation. The PrtT proteins of the invention provide means for identification of functional homologues in other species.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: September 14, 2010
    Assignee: DSM IP Assets B.V.
    Inventors: Noël Nicolaas Maria Elisabeth van Peij, Lucie Parenicova
  • Patent number: 7794975
    Abstract: The invention discloses a useful and novel factor (polypeptide) which plays an important role for morbid vascular smooth muscle in restenosis after percutaneous transluminal coronany angioplasty (PTCA) and arterial sclerosis in the field of cardiovascular system.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: September 14, 2010
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Kei Tashiro, Kazuhiro Kobuke
  • Patent number: 7794976
    Abstract: Recombinant expression vectors are provided comprising a 3?UTR of a light chain and an Epstein-Barr virus origin of replication. Also provided are host cells comprising such vectors and methods of producing recombinant protein with such vectors. Additional methods of producing a recombinant protein involve contacting cells with a first and second vector, each of which encode a different polypeptide chain, and wherein the second vector is present in an amount which is about 1.5 to 2.5 times as much as that of the first vector. Cells also can be transfected with a recombinant transient expression vector encoding a protein and are cultured in a medium in a membrane-enhanced culturing vessel to produce recombinant protein.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: September 14, 2010
    Assignee: XOMA Technology Ltd.
    Inventors: Masahisa Handa, Arnold H. Horwitz, Robyn Cotter, Eddie Batista
  • Patent number: 7794977
    Abstract: The invention relates to means and methods for regulating gene expression and production of proteinaceous molecules. The invention provides a method for producing a proteinaceous molecule in a cell comprising selecting a cell for its suitability for producing the proteinaceous molecule, providing a nucleic acid encoding the proteinaceous molecule with a nucleic acid comprising a STAR (STabilizing Anti-Repression) sequence, expressing the resulting nucleic acid in the cell and collecting the proteinaceous molecule. Providing at least one STAR sequence to a nucleic acid encoding a proteinaceous molecule will enhance production (yield) of the proteinaceous molecule by a host cell, increase the proportion of host cells with acceptable expression levels, and/or increase stability of a gene expression level.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: September 14, 2010
    Assignee: Chromagenics B.V.
    Inventors: Arie P. Otte, Arthur L. Kruckeberg, David P. E. Satijn
  • Patent number: 7794978
    Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: September 14, 2010
    Assignee: The Scripps Research Institute
    Inventors: Jason W. Chin, T. Ashton Cropp, J. Christopher Anderson, Peter G. Schultz
  • Patent number: 7794979
    Abstract: Peptide tags, referred to here as inclusion body tags, are disclosed useful for the generation of insoluble fusion peptides. The fusion peptides comprise at least one inclusion body tag operably linked to a peptide of interest. Expression of the fusion peptide in a host cell results in a product that is insoluble and contained within inclusion bodies in the cell and/or cell lysate. The inclusion bodies may then be purified and the protein of interest may be isolated after cleavage from the inclusion body tag.
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: September 14, 2010
    Assignee: E.I. du Pont de Nemours and Company
    Inventors: Qiong Cheng, Linda Jane Decarolis, Stephen R. Fahnestock, Tanja Maria Gruber, Lisa Diane Reiss, Pierre E. Rouviere
  • Patent number: 7794980
    Abstract: A chimeric polypeptide comprising an autoprocessing segment having an amino acid sequence being capable of auto-cleavage, a polynucleotide encoding such a polypeptide, and uses of such a polypeptide and such a polynucleotide are provided.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: September 14, 2010
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Shmuel Pietrokovski, Gil Amitai
  • Patent number: 7794981
    Abstract: A process is provided for the production of an antibody or a fragment or functionalized fragment thereof using a transformed lower eukaryotic host containing an example DNA sequence encoding the antibody or (functionalized) fragment thereof, wherein the antibody or (functionalized) fragment thereof is derived from a heavy chain immunoglobulin of Camelidae and is devoid of light chains, and wherein the lower eukaryotic host is a mould, preferably belonging to the genera Aspergillus or Trichoderma, or a yeast, preferably belonging to the yeast genera Saccharomyces, Kluyveromyces, Hansenula, or Pichia. The heavy chain fragment can contain at least the whole variable domain. A complementary determining region (CDR) different from the CDR belonging to the natural antibody ex Camelidae can be grafted on the framework of the variable domain of the heavy chain immunoglobulin. The catalytic antibodies can be raised in Camelidae against transition state molecules.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: September 14, 2010
    Assignee: BAC IP B.V.
    Inventors: Raymond Hamers, Cecile Hamers-Casterman, Serge V. M. Muyldermans, Leon G. J. Frenken, Cornelis T Verrips
  • Patent number: 7794982
    Abstract: This invention relates to a method for searching for a genetic polymorphism for identifying a gene whose expression level is different between alleles and to a method for searching for a phenotype-associated genetic polymorphism. More particularly, the invention relates to a method for effectively identifying a gene whose expression level is different between alleles by utilizing a genetic polymorphism present in intranuclear RNA.
    Type: Grant
    Filed: December 15, 2005
    Date of Patent: September 14, 2010
    Assignee: The University of Tokyo
    Inventors: Hiroyuki Aburatani, Shumpei Ishikawa
  • Patent number: 7794983
    Abstract: The way to design a “filled” site (which contains an interspersed element) primer set to target a particular locus is to design one of the two primers such that it encompasses that unique information (e.g., interspersed element+flanking genomic sequence+direct repeat). The way to design an “empty” site primer is to design one of the two primers such that the entire direct repeat sequence in addition to flanking genomic sequence is included on both sides. To improve efficiency, the “empty” site primer designed around the direct repeat should not be too long. This primer design of the present invention allows for the ability to test any type of interspersed genetic element containing characteristic direct repeat sequences (direct repeats). This gives the option of many new polymorphic marker sites because Alu elements are not the only interspersed genetic elements having direct repeats flanking their core sequence.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: September 14, 2010
    Assignee: Life Genetics Lab, LLC.
    Inventors: Sudhir K. Sinha, Anthony B. Carter
  • Patent number: 7794984
    Abstract: A novel use of a template-dependent polymerase. The novel use is effected by employing the template-dependent polymerase for incorporating at least one oligonucleotide triphosphate onto a nascent oligonucleotide-3?-OH in a template-dependent manner.
    Type: Grant
    Filed: December 26, 2007
    Date of Patent: September 14, 2010
    Assignee: Yeda Research and Development Co. Ltd.
    Inventor: Hadar Kless
  • Patent number: 7794985
    Abstract: A method for detecting the presence of a nucleic acid template (110) in a sample includes the steps of combining the sample in a reaction vessel with a first primer (112F) and a second primer (112R) having a first section (114), a second section (118) and a spacer (116). The method also includes one or more of the steps of extending the first section (114) with additional nucleotides, binding the first primer (112F) to the extended first section, extending the first primer (112F) with additional nucleotides and terminating extension of the first primer (112F) with the spacer (116). The first section (114) includes a plurality of nucleotides that bind with a portion of the nucleic acid template (110). The second section (118) is spaced-apart from the first section (114) and includes a plurality of nucleotides that do not bind with the nucleic acid template (110). The spacer (116) couples the first section (114) to the second section (118). The invention is also directed toward the second primer (112R).
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: September 14, 2010
    Assignee: GHC Technologies, Inc.
    Inventor: Daniel D. Shoemaker
  • Patent number: 7794986
    Abstract: The invention relates to a method for amplification of a target RNA sequence, wherein the first primer comprises a hybridizing sequence of 7 to 14 nucleotides, which is capable of binding to a first segment of the target RNA sequence, a transcription enhancing sequence, and an anchor which is capable of binding to a second segment of the target RNA sequence, and/or wherein the second primer comprises a hybridizing sequence of 7 to 14 nucleotides, an amplification enhancing sequence and an anchor which is capable of binding to a second segment of the first single stranded cDNA. The invention further relates to primers for the amplification of target RNA sequences and to a kit comprising one or more of the primers.
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: September 14, 2010
    Assignee: Biomerieux B.V.
    Inventors: Birgit Alberta Louisa Maria Deiman, Arnoldina Margaretha Wilhelmina Strijp
  • Patent number: 7794987
    Abstract: The present invention concerns the use of compounds for treating central neuropathic pain.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: September 14, 2010
    Assignee: UCB Pharma GmbH
    Inventor: Thomas Stoehr
  • Patent number: 7794988
    Abstract: The present invention provides a method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family, particularly a bacterium belonging to genus Escherichia or Pantoea, which has been modified to attenuate expression of the rspAB operon.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: September 14, 2010
    Assignee: Ajinomoto Co., Inc.
    Inventors: Dmitriy Vladimirovich Filippov, Elvira Borisovna Voroshilova, Mikhail Markovich Gusyatiner
  • Patent number: 7794989
    Abstract: A coryneform bacterium that is modified by using a yggB gene so that L-glutamic acid-producing ability is enhanced as compared to a non-modified strains is cultured in a medium to cause accumulation of L-glutamic acid in the medium or bacterial cells, and L-glutamic acid is collected from the medium or cells.
    Type: Grant
    Filed: December 28, 2005
    Date of Patent: September 14, 2010
    Assignee: Ajinomoto Co., Inc.
    Inventors: Jun Nakamura, Seiko Hirano, Hisao Ito
  • Patent number: 7794990
    Abstract: Provided are a microorganism of Corynebacterium genus that has an inactivated endogenous NCgl1835 gene therein and produces L-lysine, and a method of producing L-lysine using the same.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: September 14, 2010
    Assignee: CJ Cheiljedang Corporation
    Inventors: Young Hoon Park, Hyun Min Koo, Sang Jo Lim, Jun Ok Moon, So Yeon Rah, Young Lyeol Yang
  • Patent number: 7794991
    Abstract: The present invention relates to novel stemphones having enhancing effect of ?-lactam antibiotic used as an antibacterial agent, and a process for production thereof. The process is comprised of culturing microorganism belonging to genus Aspergillus and having ability to produce stemphones, the microorganism of which is Aspergillus sp. FKI-2136 NITE BP-83, accumulating the stemphones in the cultured mass, and isolating the stemphones from the cultured mass. Since the obtained stemphones have an action enhancing activity of ?-lactam antibiotic used as an antibacterial agent by combining with ?-lactam antibiotic, the stemphones are expected to be useful as the therapeutic agent for MRSA infection and infectious diseases caused by multi-drug resistant microorganisms including ?-lactam antibiotic resistance.
    Type: Grant
    Filed: October 3, 2005
    Date of Patent: September 14, 2010
    Assignee: The Kitasato Institute
    Inventors: Satoshi Omura, Hiroshi Tomoda, Rokuro Masuma
  • Patent number: 7794992
    Abstract: The present invention relates to the use of recombinant silicatein-? or silicatein-? isolated from natural sources as well as to silicatein-?-fusion proteins as well as silicatein-?-related enzymes for the synthesis, the degradation and for modification of silicon dioxide (condensation products of silicic acid, silicates), silicones and other silicon(IV)- or metal(IV)-compounds, and their technical uses.
    Type: Grant
    Filed: November 9, 2004
    Date of Patent: September 14, 2010
    Assignee: NanotecMARIN GmbH
    Inventors: Werner E. G. Müller, Heiko Schwertner, Heinz C. Schröder
  • Patent number: 7794993
    Abstract: The present invention relates to a polypeptide having an activity to asymmetrically reduce (3S)-1-chloro-3-tert-butoxycarbonylamino-4-phenyl-2-butanone to produce (2R,3S)-1-chloro-3-tert-butoxycarbonylamino-4-phenyl-2-butanol isolated from a microorganism belonging to the genus Ogataea, a DNA encoding the polypeptide and a transformant that produces the polypeptide. The present invention moreover relates to a method of producing (2R,3S)-1-chloro-3-tert-butoxycarbonylamino-4-phenyl-2-butanol utilizing the polypeptide or the transformant. Using the polypeptide or transformant of the present invention, optically active alcohols such as (2R,3S)-1-chloro-3-tert-butoxycarbonylamino-4-phenyl-2-butanol and the like can be produced efficiently.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: September 14, 2010
    Assignee: Kaneka Corporation
    Inventors: Noriyuki Kizaki, Miho Yano, Masahiro Funaki, Teruaki Takesue, Yoshihiko Yasohara, Souichi Morikawa, Takahisa Nakai, Michihiko Kataoka, Sakayu Shimizu